Cefoxitin
Cefoxitin (cefoxitin) is a small molecule pharmaceutical. Cefoxitin was first approved as Mefoxin on 1982-01-01. It is used to treat abscess, bacterial infections, bacterial skin diseases, bacteroides infections, and clostridium infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Cefoxitin (discontinued: Cefoxitin, Mefoxin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefoxitin sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER | B. Braun Medical | N-065214 RX | 2006-03-10 | 2 products, RLD, RS |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cefoxitin | ANDA | 2025-03-03 |
| cefoxitin and dextrose | New Drug Application | 2019-07-29 |
Indications
FDA
EMA
Show 9 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0694 | Injection, cefoxitin sodium, 1 gm |
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Communicable diseases | D003141 | — | — | — | 1 | — | 2 | 3 | 6 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | 1 | 1 | 3 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | 2 | 1 | 3 |
| Critical illness | D016638 | — | — | — | — | — | 1 | 1 | 2 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | — | 1 | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | 1 | — | 1 |
| Prophylactic surgical procedures | D065286 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | 1 | — | 2 | 3 |
| Surgical wound infection | D013530 | — | — | 1 | — | 1 | — | 1 | 3 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | 1 | — | — | 2 |
| Antibiotic prophylaxis | D019072 | — | — | — | — | 1 | — | 1 | 2 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | 1 | — | — | 1 |
| Mycobacterium infections | D009164 | — | A31.9 | — | 1 | 1 | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | 1 | — | — | 1 |
| Pancreatic diseases | D010182 | — | K86.9 | — | — | 1 | — | — | 1 |
| Toxemia | D014115 | — | — | — | — | 1 | — | — | 1 |
| Diabetic foot | D017719 | EFO_1001459 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | 7 | 8 |
| Appendicitis | D001064 | EFO_0007149 | K37 | 1 | 1 | — | — | 1 | 3 |
| Endometritis | D004716 | EFO_1001312 | — | — | 1 | — | — | 1 | 2 |
| Wound infection | D014946 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Focus groups | D017144 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory tract infections | D012141 | — | J06.9 | — | — | — | — | 3 | 3 |
| Infectious pregnancy complications | D011251 | — | — | — | — | — | — | 1 | 1 |
| Bacterial infections | D001424 | — | A49 | — | — | — | — | 1 | 1 |
| Acute kidney injury | D058186 | — | N17 | — | — | — | — | 1 | 1 |
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 1 | 1 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Bariatric surgery | D050110 | — | — | — | — | — | — | 1 | 1 |
| Neural tube defects | D009436 | — | Q00.0 | — | — | — | — | 1 | 1 |
| Spinal dysraphism | D016135 | EFO_1001210 | Q05 | — | — | — | — | 1 | 1 |
Show 19 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cefoxitin |
| INN | cefoxitin |
| Description | Cefoxitin is a semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase. It has a role as an antibacterial drug. It is a cephalosporin, a semisynthetic derivative, a beta-lactam antibiotic allergen and a cephamycin. It is a conjugate acid of a cefoxitin(1-). |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21 |
Identifiers
| PDB | — |
| CAS-ID | 35607-66-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL996 |
| ChEBI ID | 209807 |
| PubChem CID | 441199 |
| DrugBank | DB01331 |
| UNII ID | 6OEV9DX57Y (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 20,290 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
903 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use